Thira Rojasawasthien

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Top Venues

Molecules (Basel, Switzerland)

FASEB bioAdvances

This page only lists publications with an associated author ORCID identifier.

Publications

Takumi Ito, Thira Rojasawasthien, Sachiko Yamashita Takeuchi, Hideto Okamoto, Nobuaki Okumura, Tomohiko Shirakawa, Takuma Matsubara, Tatsuo Kawamoto, Shoichiro Kokabu
Royal Jelly Enhances the Ability of Myoblast C2C12 Cells to Differentiate into Multilineage Cells. Molecules (Basel, Switzerland) 29 (7) (2024)
Takumi Ito, Thira Rojasawasthien, Sachiko Yamashita Takeuchi, Hideto Okamoto, Nobuaki Okumura, Tomohiko Shirakawa, Takuma Matsubara, Tatsuo Kawamoto, Shoichiro Kokabu
Royal Jelly Enhances the Ability of Myoblast C2C12 Cells to Differentiate into Multilineage Cells. Molecules (Basel, Switzerland) 29 (7) (2024)
Takumi Ito, Thira Rojasawasthien, Sachiko Yamashita Takeuchi, Hideto Okamoto, Nobuaki Okumura, Tomohiko Shirakawa, Takuma Matsubara, Tatsuo Kawamoto, Shoichiro Kokabu
Royal Jelly Enhances the Ability of Myoblast C2C12 Cells to Differentiate into Multilineage Cells. Molecules (Basel, Switzerland) 29 (7) (2024)
Thira Rojasawasthien, Michihiko Usui, William N Addison, Takuma Matsubara, Tomohiko Shirakawa, Toshiyuki Tsujisawa, Keisuke Nakashima, Shoichiro Kokabu
Nobiletin, a NF-κB signaling antagonist, promotes BMP-induced bone formation. FASEB bioAdvances 5 (2) (2022)
Thira Rojasawasthien, Michihiko Usui, William N Addison, Takuma Matsubara, Tomohiko Shirakawa, Toshiyuki Tsujisawa, Keisuke Nakashima, Shoichiro Kokabu
Nobiletin, a NF-κB signaling antagonist, promotes BMP-induced bone formation. FASEB bioAdvances 5 (2) (2022)